Story
Sling Therapeutics Secures $123M to Fund Phase 3 Trial for Oral Thyroid Eye Disease Drug
Summary
Sling Therapeutics has raised $123 million in a Series C round led by Forbion to fund a pivotal Phase 3 study for linsitinib, its oral drug candidate for thyroid eye disease.
Sling Therapeutics has secured $123 million in a Series C financing round to advance its oral drug candidate, linsitinib, into a global Phase 3 trial for the treatment of thyroid eye disease (TED). The funding positions the company to challenge existing injectable treatments for the rare autoimmune condition.
Funding and Trial Advancement
The financing was led by Forbion and included participation from new investor Sectoral Asset Management and existing investor TPG Life Sciences Innovations. The proceeds are designated to fund the Phase 3 ORBIT trial, a global study enrolling adults with moderate to severe active TED.
Sling Therapeutics said the trial's design was established in agreement with the U.S. Food and Drug Administration (FDA) following an End-of-Phase 2 meeting earlier this year. "The data generated to date give us confidence in linsitinib’s potential to meaningfully address important limitations of current TED therapies," said Sling Chief Executive Ryan Zeidan.
Linsitinib's Clinical Profile
Linsitinib is an oral medication that targets the insulin-like growth factor 1 receptor (IGF-1R), a validated target in TED that is also used by currently approved therapies. The drug's oral delivery method distinguishes it from existing treatments, which require infusion or injection.
AdA completed Phase 2b/3 trial met its primary endpoint of reducing proptosis, the forward bulging of the eyes characteristic of the disease. According to the company, the drug also demonstrated a favorable safety profile with fewer concerns related to:
- Hearing impairment
- Blood sugar changes
- Menstrual cycle alterations
Market and Regulatory Context
The FDA has granted linsitinib Fast Track designation, a status intended to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. This can lead to more frequent agency interactions and eligibility for accelerated approval and priority review.
Thyroid eye disease is a rare condition that affects more than 200,000 people in the United States, primarily women with Graves' disease. The condition causes inflammation and tissue buildup behind the eyes, which can impair vision in severe cases. Linsitinib has been evaluated in over 900 patients across 15 clinical trials for various diseases, according to Sling.
Read next
More on Stocks
ExxonMobil in Advanced Talks for Venezuela Return, Eyeing Former Orinoco Project
The U.S. oil major is reportedly negotiating a return to the Petromonagas heavy oil project, a significant reversal nearly two decades after its assets were nationalized by the Venezuelan government.
US House Passes Bill Targeting Data Center Power Grid Costs
The U.S. House of Representatives has advanced the Ratepayer Protection Act, the first legislation of its kind aimed at making large power users like data centers bear the costs of new electricity infrastructure.
New Zealand's Q2 GDP Growth Exceeds Forecasts but Remains Tepid at 0.2%
New Zealand's economy grew 0.2% in the second quarter, topping analyst and central bank forecasts, according to official data. However, the pace of expansion remains slow amid persistent economic headwinds and recent interest rate hikes.
Snap Partners With Salesforce, Nvidia to Target Enterprise Market With AR Glasses
Snap Inc. has announced strategic partnerships with Salesforce, Nvidia, and Amazon Web Services to integrate enterprise-grade AI and software tools into its Specs augmented-reality glasses, signaling a major push into the corporate market.